Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar;16(2):275-282.
doi: 10.1016/j.jcf.2016.07.008. Epub 2016 Jul 29.

Hyperpolarized 129Xe for investigation of mild cystic fibrosis lung disease in pediatric patients

Affiliations

Hyperpolarized 129Xe for investigation of mild cystic fibrosis lung disease in pediatric patients

Robert P Thomen et al. J Cyst Fibros. 2017 Mar.

Abstract

Background: Cystic fibrosis (CF) is a genetic disease which carries high morbidity and mortality from lung-function decline. Monitoring disease progression and treatment response in young patients is desirable, but serial imaging via CT is often considered prohibitive, and detailed functional information cannot be obtained using conventional imaging techniques. Hyperpolarized 129Xe magnetic resonance imaging (MRI) can depict and quantify regional ventilation, but has not been investigated in pediatrics. We hypothesized that 129Xe MRI is feasible and would demonstrate ventilation defects in mild CF lung disease with greater sensitivity than FEV1.

Methods: 11 healthy controls (age 6-16years) and 11 patients with mild CF (age 8-16years, Forced Expiratory Volume (FEV1) percent predicted >70%) were recruited for this study. Nine CF patients had an FEV1>85%. Each subject was imaged via hyperpolarized 129Xe MRI, and the ventilation defect percentage (VDP) was measured. FEV1 and VDP were compared between the groups.

Results: FEV1 for controls was 100.3%±8.5% (mean±sd) and for CF patients was 97.9%±16.0% (p=0.67). VDP was 6.4%±2.8% for controls and 18.3%±8.6% for CF (p<0.001). When considering the 9 CF patients with normal FEV1 (>85%), the mean FEV1 was 103.1%±12.3% (p=0.57 compared to controls) and VDP was 15.4%±6.3% (p=0.002).

Conclusions: Hyperpolarized 129Xe MRI demonstrated ventilation defects in CF patients with normal FEV1 and more effectively discriminated CF from controls than FEV1. Thus 129Xe may be a useful outcome measure to detect mild CF lung disease, to investigate regional lung function in pediatric lung diseases, and to follow disease progression.

Keywords: Cystic fibrosis; Hyperpolarized; Mri; Pediatric.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Plot of whole-lung VDP in control (•) and CF (○) cohorts. VDP was plotted as a function of defect threshold (expressed as percentage of whole-lung signal mean) and the difference between CF and control defect percentages (▲), illustrating the greatest difference near a 60% defect threshold. Lines extending from data points are standard-deviation error bars. Control patient #5 was imaged twice, and both image sets were included here (hence n = 12 for controls).
Figure 2
Figure 2
Axial HP 129Xe MRI slices of Healthy Control #10, CF patient #9 (highest VDP), and CF patient #7 (high FEV1 and VDP) both with and without defect voxels identified.
Figure 3
Figure 3
Hyperpolarized 129Xe images in healthy volunteer #5, with and without defect voxels colored, using 129Xe hyperpolarized in a homebuilt polarizer (top) and commercial polarizer (bottom). Mean VDP for this patient was 8.6% (higher than our mean for controls, detailed in Table 2).
Figure 4
Figure 4
A: Plot of FEV1 vs VDP for all subjects (healthy, filled symbols; CF, open symbols) demonstrating the wide range of ventilation defects among the near-normal FEV1 values. Solid lines are control means, dashed lines are CF means. B: Bar plot showing mean for FEV1 for control and CF populations. C: Bar plot showing mean VDP for control and CF populations. Error bars are standard deviations. Individual numeric data are provided in Table 2.

Comment in

References

    1. Ikpa PT, Bijvelds MJ, de Jonge HR. Cystic fibrosis: toward personalized therapies. Int J Biochem Cell Biol. 2014;52:192–200. - PubMed
    1. Organization WH. The molecular genetic epidemiology of cystic fibrosis Human Genetics Programme: Chronic Diseases and Health Promotion. 2004
    1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373(9678):1891–1904. - PubMed
    1. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, Joseloff E, Ramsey BW Network GIotCFFTD. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med. 2014;190(2):175–184. - PMC - PubMed
    1. de Jong PA, Ottink MD, Robben SG, Lequin MH, Hop WC, Hendriks JJ, Pare PD, Tiddens HA. Pulmonary disease assessment in cystic fibrosis: comparison of CT scoring systems and value of bronchial and arterial dimension measurements. Radiology. 2004;231(2):434–439. - PubMed